Expert Recommendations in Relapsed/Refractory Multiple Myeloma

In this on demand webcast, expert faculty discuss best practices in treating patients
with relapsed/refractory multiple myeloma. 

MYSummit Myeloma Conference - March 30–April 1, 2023

The MYSummit Conference has been rescheduled to March 30 – April 1, 2023

Details to Follow

Myeloma News

Keep up to date on the latest multiple myeloma news and information.

Featured Content

Myeloma News

Recent Publications

High-dose carfilzomib achieves superior anti-tumor activity over lowdose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex

Haematologica. 2023 Feb 2. doi: 10.3324/haematol.2022.282225. Online ahead of print. ABSTRACT The optimal carfilzomib dosing is a matter of debate. We analyzed the inhibition profiles of proteolytic proteasome subunits β5, β2 and β1 after low-dose (20/27 mg/m2) versus...

Twitter Discussions